Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.641371
Title: Immunological abnormalities in patients with haemophilia : role of factor VIII concentrate
Author: Batchelor, Alison
Awarding Body: University of Edinburgh
Current Institution: University of Edinburgh
Date of Award: 1993
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
Intermediate purity factor VIII concentrates have greatly improved care for haemophilia sufferers but have been implicated in contributing to subclinical immunodeficiency observed in vivo. During the course of factor VIII replacement therapy haemophilia patients are reepatedly exposed to an enormous number of allogeneic protein contaminants and this substantial protein load may be responsible for establishing immunological abnormalities. Indeed, it has been proposed that intermediate purity factor VIII concentrates could accelerate the rate of disease progresssion in those haemophiliacs infected with the human immunodeficiency virus. Highly purified factor VIII preparations are now available commercially, but are extremely expensive compared to conventional intermediate purity concentrates and their use must therefore be justified in terms of patient benefit. I have set out to investigate whether intermediate purity factor VIII concentrates could contribute significantly to immune abnormalities observed in haemophilia patients in vivo. I have approached this problem by investigating the effects of various factor VIII preparations on immune stimulation in vitro. My results demonstrate that intermediate purity factor VIII concentrates can modulate lymphocyte proliferation in vitro. In contrast, highly purified factor VIII preparations have no effect on immune stimulation in this system. Although I have failed to identify the factor(s) responsible for the observed immune modulation in vitro I have excluded a number of potential candidates. The inhibitory effects of factor VIII preparations on lymphocyte proliferation previously demonstrated in vitro are probably not related directly to observed abnormalities in haemophilia patients in vivo. Immune alterations in vivo may be related to stimulation, rather than suppression of the immune system. My findings have a bearing on these stimulatory effects and suggest that the use of highly purified factor VIII preparations in the treatment of haemophilia is justified.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.641371  DOI: Not available
Share: